ABSTRACT
INTRODUCTION
Oligodeoxyribonucleoside phosphorothioates (S-ODNs) have been shown to block the de novo infection of susceptible cells by the human immunodeficiency virus (HTV-1) and to inhibit viral expression and proliferation in already infected cells (1-7). The ability to block de novo HTV-1 infection appears to be a common property of S-ODNs (3, 6, 7) , whereas the ability to inhibit expression in already infected cells is specific to S-ODN sequences that are complementary ('antisense') to viral-derived RNA (2, 6, 7) . The blocking of de novo infection by S-ODNs is both composition-dependent and length-dependent; as examples, S-dC 2 g is a better inhibitor than S-dA^ and S-dC^ is a better inhibitor than S-dC M (3) . In a de novo infection assay, phosphoric acid diester linked homo-oligomers, such as the a or /3 forms of dC28, show either no inhibitory effect (3, 7) or a significantly reduced inhibitory effect relative to the corresponding phosphorothioates (6) . These findings suggest that it is the P(O)S~ functionality that is fundamentally responsible for the potent anti-HTV-1 activity of S-dC;>8 (JDso) 0-1 /*M). In order to shed additional light on the molecular basis for the anti-HTV activity of phosphorothioates and to aid in developing more potent analogs, we have initiated studies with stable, phosphorothioate sequences wherein the nucleoside base has been deleted. We herein report the synthesis of, and anti-HTV activity of, two abasic 28-mers, d[Cps(Eps)26]C, 1, and d[Cps(Vps)2 6 C, 2, wherein 'E' and 'V derive from 1, 2-dideoxy-D-ribofuranose, 3, and (±)-butane-l, 3-diol, 4, respectively.
EXPERIMENTAL
General methods. Nuclear magnetic resonance spectra were obtained on either JEOL GSX-500 or General Electric GN-300 spectrometers. Proton and carbon NMR spectra are reported in parts per million (ppm) relative to tetramethyl silane (TMS) for organic solutions and sodium 3-trimethylsilyl-2,2,3,3,-d 4 propionate (TSP) for aqueous solutions.
3I P-NMR are reported in ppm relative to external aqueous trimethyl phosphate.
Melting points (uncorrected) were determined on a Buchi 510 melting point apparatus. Analytical thin layer chromatography (TLC) was earned out using silica gel 60 F254 pre-coated sheets Gayer thickness, 0.2 mm). Materials were visualized on the TLC plates by either ultraviolet light, iodine vapors, HC1 fumes, or charring following spraying with concentrated sulfuric acid The oligodeoxynucleoside phosphorothioate, 1, was synthesized on an Applied Biosystems, Inc. Model 38OB DNA Synthesizer.
Toluene, triethylamine, and acetonitrile were distilled from CaH 2 after first refluxing for several hours. Pyridine was distilled from anhydrous KOH pellets following several hours reflux. Anhydrous ether (Mallinckrodt Chemicals) was passed through a column of activated alumina to remove peroxides. Methanol was dried by fractional distillation in the presence of a small amount of sodium metal. Acetic acid was rendered anhydrous by fractional distillation of glacial acetic acid in the presence of acetic anhydride. All other solvents and chemicals were reagent grade.
Cytopathic effect of HIV-1 on H9 cells: Phosphorothioate Inhibition Assay. The ability to block the cytopathic effect of the HTV-1 virus on H9 cells was assayed as described (3). 8 . Dry toluene (225 mL) was placed in a 500 mL flask at ambient temperature, degassed, and blanketed with argon; the chloro compound (2.42 g; 6.2 mmol), 7, prepared as described (9) , was added to * To whom correspondence should be addressed the toluene under argon. To this solution was added 2,2'-azobis(2-methylpropionitile) (1.02 g; 6.2 mmol) followed by tri-n-butyltin hydride (2.2 mL; 7.7 mmol). The reaction mixture was heated for 6 h at 70-80°C for an additional 10 h. Toluene was removed under vacuum (at < 35°C) and the crude product was purified by chromatography over silica gel (5x30 cm column). Elution with methylene chloride:hexane (25:75 v/v) gave 8 as a white solid (2.1 g; 95% yield); TLC (methylene chloride) showed one spot with Rf 0. 6 1, 2-Dideoxy-D-ribojuranose, 3. Compound 3 was prepared as a colorless oil according to a described procedure (9) .
[Proton assignments were based on the results of 2D NMR COSY (at 300 MHz) and selective proton irradiation experiments (at 500 MHz).] 9 . The ribofuranose, 3, was dissolved in dry pyridine (10 mL) and freshly recrystallized 4,4'-dimethoxytrityl chloride (2.1 g, 6.2 mmol) was added at 25 °C. The progress of the reaction was monitored by TLC (toluene:CH 2 Cl 2 :methanol, 1:1:0.02). After 2 h, 1 mL of methanol was added to the reaction mixture which was then stirred for an additional 30 min. After the solvents were evaporated under vacuum, the resulting dry residue was dissolved in methylene chloride and then extracted with water (2x2 mL). The CH 2 C1 2 layer was dried over anhydrous magnesium sulfate. Methylene chloride was removed under vacuum to give the tntyl derivative which was purified by chromatography on silica gel (2.5x17 cm column) using a stepwise gradient of toluene:CH 2 Cl 2 :methanol (1:1:0.02). The trityl groupcontaining fractions (visualized on TLC plates as orange spots using HC1 fumes) were pooled and the eluting solvent mixture evaporated to give the pure trityl derivative as a heavy yellow oil (1.88 g, 75%). To a solution of the trityl ether in dry methylene chloride (5 mL) and triethyl amine (3.7 mL, 2.7 g, 27 mmol), was added 2-cyanoethyl-N,N-diisopropylamino phosphorochloridite (1.2 g, 4.7 mmol) dropwise at room temperature with constant stirring. After 0.5 h, the solvents were removed under vacuum. The resulting residue was column chromatographed on silica gel using a stepwise gradient from toluene to toluene:triethyl amine (1:0.1). The desired fractions (Rf = 0.6) were pooled and the solvent removed under vacuum. The residue was dried under high vacuum to give the phosphoramidite, 9, as a heavy oil (2.6 g, 80% 10 . A solution of tetrazole in acetonitnle (12 mL, 0.5 M) was added to the phosphoramidite 9 (1.6 g). Water (1 mL) was then added to the reaction mixture with stirring. After 10 min, triethylamine (10 ml) was added; the reaction mixture was kept at 25 °C for 10 hours. The extent of reaction was monitored by TLC (silica gel, CHCl 3 :MeOH, 20:1). The reaction mixture was evaporated to dryness in vacua and the crude reaction mixture was loaded onto a silica gel column (25x1.5 cm) and the desired product was eluted with a stepwise gradient from CHC1 3 to CHCl 3 -MeOH (10:0.1). The product-containing fractions were pooled and, after removal of solvent under vacuum, gave 10 as a glassy solid (820 mg, 63%). 31P NMR: 5 -0.5 (d, "JEp.^ = 605 Hz). 
5-O-4,4'-dimethoxytrityl-l,2-dideoxy-u-ribofuranose-3-O-(2-cyanoethyl-N,N -diisopropyl) phosphoramidite,

Oligophosphorothioate d[CE PS (E PS
)
Oligophosphorothioate d[CE PS (V PS ) 2 6C], 2.
The oligophosphorothioate, 2, was synthesized as described (10) .
RESULTS
The synthesis of 1, 2-dideoxy-D-ribofuranose was carried out as shown in Scheme I, starting from 2-deoxy-D-ribose, using modifications of reported procedures (8, 9) . The conversion of 5 to the chloro-sugar, 7, via the 1-Omethyl deoxyriboside, 6, was carried out using reported procedures (9) . Reductive dechlorination of 7 with tri(/i-butyl)tin hydride gave 8, which on alkaline hydrolysis gave 3. The overall isolated yield of 3, based on starting 2-deoxy-D-ribose, was 51%. Conversion of 3 to its 5-O-trityl ether and subsequent phosphitylation gave the phosphoramidite, 9, which, after treatment with tetrazole in the presence of water/triethylamine, gave the desired H-phosphonate, 10. The monomer, 10, was incorporated into 1 using a modification (11) of standard, H-phosphonate DNA chemistry (12, 13) ; the sulfurization of the internucleotidic H-phosphonate linkages was carried out manually (14) . The oligomer, 1, was purified by reverse phase HPLC; the 31 P-NMR spectrum of 1 The oligomers, 1 and 2, were evaluated for their ability to block the denovo HTV-1 infection of H9 cells; see Figure 1 . The assay, which has been described elsewhere (3), monitors the effectiveness of drugs to block or ameliorate the cytopathic effects of HTV-1 replication on H-9 cells. The homo-ohgomer, S-dC 28 , has been shown to be a potent and non-toxic inhibitor of the HTV-1 de novo infection of H9 cells (3), and was used as a standard in the assay of 1 and 2; in the presence of 0.1 /iM S-dC28, the number of viable H9 cells, following HIV-1 exposure, is doubled relative to the S-dC^ untreated population (see Figure 1) . A two-fold increase in H-9 cell viability could also be obtained with 2, but at an approximately 20-fold higher concentration (2.0 /im) than that needed using S-dC^. The deoxy ribosyl-based sequence, 1, required an even higher concentration (5-10 /iM) to achieve a two-fold increase in H-9 cell viability. Compound 2 appeared to be slightly toxic, producing an approximately 25% reduction in cell viability at the higher concentrations.
DISCUSSION
On the basis of the data presented above, it is clear that the nucleotide base has a definite, and enhancing, influence on the overall activity of S-ODNs in blocking de novo HIV-1 infection. The mechanisms by which the various phosphorothioates act are still, however, uncertain. Recently, it has been shown that SdC28 is an inhibitor, at the micromolar level, of HTV-1 reverse transcnptase (15) ; the in vitro activity of S-dC 28 against HTV-1 is undoubtedly associated with this inhibition of reverse transcriptase. However, it appears likely that additional mechanisms of action are involved with S-dC^. In this regard, Stein and co-workers (16) , and ourselves (17) , have noted that S-dC 2 8 inhibits syncytia formation between infected and uninfected cells, even in reverse transcriptase defective virions (16) , suggesting that S-dC2g blocks surface interactions between these cells.
At present, we do not know the ability of 1 and 2 to inhibit HIV-1 reverse transcriptase activity (18) , nor do we know the extent to which 1 and 2 are taken up by cells, although both of these studies are now in progress. Recently, we have shown that an antisense phosphorothioate 28-mer against the rev geneencoded RNA of HTV-1 is efficiently taken up by a variety of cell types (19) and, in the absence of evidence to the contrary, we assume that S-dC 28 is also efficiently taken up by cells. The influence of the nucleotide base, as opposed to the DNA backbone, on cellular uptake is not, as yet, known and we cannot extrapolate to the behavior of 1 and 2 on the basis of the oligonucleoside phosphorothioate mentioned above. We do know, however, that 1 binds tightly to cell surfaces (more so than does S-dC 28 (20) ), and it may well be the case that 1 and 2 act only at the cell surface, whereas S-dC 2 g acts at the cell surface to block HIV-1 entry and internally to inhibit HTV-1 reverse transcription; we hope to resolve these issues in the near future. On the basis of model enzyme studies (10) , it is reasonable to assume that 1 and 2 have lifetimes under the assay conditions that are comparable to that of S-dC 28 ; thus, our observed differences in activity against HTV-1 do not stem from differences in rates of enzymically-catalyzed hydrolysis.
Although a number of mechanistic issues and questions, still unresolved, have been raised by the current study, it is nonetheless apparent that, for clinical purposes, the abasic analogs that are herein presented should be considerably less useful than the homo-pyrimidine phosphorothioates.
